Cutting-edge health science,
without the hype.
Peptides, longevity, metabolism and emerging therapeutics — explained clearly, graded honestly, with the uncertainty left in.
- Source-linked research
- Review process published
- Regulatory status by country
- Uncertainty stated plainly
Everything in one place
Understand it, then get help with it
Most peptide sites sell you something. A few explain the science. Biolivon does the explaining — and then connects you to people qualified to act on it.
Evidence-graded dossiers
Every compound gets the same structure, an honest grade, and a plain statement of what is still unknown.
Verified practitioners
Physicians, dietitians and coaches with registration, qualifications and conflicts checked before they are listed.
GLP-1 care with support
A doctor prescribes, a coach supports, and a maintenance plan exists from day one — not after the weight comes back.
Quality Lab
Identity versus purity, HPLC, mass spectrometry, endotoxin, stability — and what a certificate quietly leaves out.
Regulatory watch
FDA, CDSCO and EMA developments, with process steps never dressed up as approvals.
The Biolivon app
Client, coach and clinician working from one shared plan — with medication questions routed to the doctor automatically.
Explore by scientific area
Start where your question is
Each area collects the dossiers, studies, trials and regulatory events that belong to it — with the evidence grade attached to every claim.
Peptide Science
What peptides are, how they signal, and how the evidence is built.
Explore →Metabolic Health
Glucose regulation, incretin biology, weight and cardiometabolic risk.
Explore →Mitochondrial Health
Energy production, mitochondrial stress signalling and cardiolipin biology.
Explore →Healthy Aging
Biological aging, senescence, and what ageing biomarkers can and cannot show.
Explore →Brain and Cognition
Neuroplasticity, cognition research, and the limits of nootropic claims.
Explore →Muscle and Recovery
Tissue repair, tendon and muscle biology, and recovery research.
Explore →Sleep and Circadian Biology
Sleep architecture, circadian timing and the peptides studied around them.
Explore →Skin and Hair Science
Topical peptides, collagen signalling, and what penetrates skin at all.
Explore →Hormonal Health
The HPG axis, gonadotropins, and where endocrine practice and grey-market use overlap.
Explore →Sexual Health
Melanocortin and kisspeptin pathways, and the gap between one approval and its analogues.
Explore →Peptide intelligence
Understand the evidence before the claims
Every dossier carries an evidence grade, states regulatory standing per jurisdiction, and says plainly whether it has been reviewed yet.
Semaglutide
Approved therapeutic
Research focus. GLP-1 receptor agonism in type 2 diabetes, weight management and cardiovascular risk.
- Human studies
- 2
- Trials
- 1
- Safety signals
- 3
Last reviewed 28 Jul 2026
Tirzepatide
Approved therapeutic
Research focus. Dual GIP and GLP-1 receptor agonism in type 2 diabetes and obesity.
- Human studies
- 1
- Trials
- 1
- Safety signals
- 1
Last reviewed 20 Jul 2026
Retatrutide
Investigational compound
Research focus. Triple GIP, GLP-1 and glucagon receptor agonism in obesity and metabolic disease.
- Human studies
- 1
- Trials
- 1
- Safety signals
- 2
Last reviewed 30 Jul 2026
BPC-157
Investigational compound
Research focus. Tissue-repair signalling in tendon, muscle and gastrointestinal models.
- Human studies
- 0
- Trials
- 0
- Safety signals
- 2
Last reviewed 31 Jul 2026
MOTS-c
Mitochondrial peptide
Research focus. Mitochondrial-derived peptide signalling in metabolic regulation and exercise physiology.
- Human studies
- 1
- Trials
- 0
- Safety signals
- 1
Last reviewed 18 Jul 2026
GHK-Cu
Cosmetic / topical peptide
Research focus. Copper-binding tripeptide signalling in skin remodelling and wound repair.
- Human studies
- 1
- Trials
- 0
- Safety signals
- 1
Last reviewed 30 Jun 2026
Understanding the science is the first half. The second half is a clinician who knows your history.
Biolivon connects you to verified physicians, dietitians and coaches for metabolic and GLP-1 care — prescribing decisions with a doctor, nutrition and training support alongside them, and everything held in one shared plan.
Clients
Track your plan, log how you actually feel, and message your care team.
Coaches
Training, nutrition and habits inside a written scope. Medication questions route to the clinician.
Practitioners
Hold the prescribing decisions, review coach notes, oversee a caseload.
Research pulse
What changed this week?
Published human studies, new trials, status changes, regulatory announcements, corrections and safety findings — with our read on what each one does and does not show.
- Regulatory
Compounding advisory discussion is not an approval — reading the July record
A committee discussing or nominating a substance tells you the substance is being examined. It does not tell you the substance works, is safe, or may be sold. We break the July record into our five standings: under consideration, recommended, listed, approved, not approved.
- Human studyPromising
Post-discontinuation weight regain after incretin therapy
Follow-up data continue to show substantial regain after stopping. The clinically useful question is shifting from how much weight comes off to what a durable maintenance plan looks like.
- SafetyEstablished
Mislabelled peptide products found in independent testing
Identity and purity failures continue to appear in consumer-directed peptide products. This is a supply-chain risk that exists independently of whether a molecule has any biological merit.
- Correction
Correction: BPC-157 regulatory note
Our earlier note could be read as implying that compounding-committee consideration indicated progress toward approval. It does not. The note has been rewritten and the change logged on the dossier.
- New trial
New phase 3 registration in the triple-agonist class
Registration is a milestone in a development programme, not a result. We will report outcomes when they are published, not when they are announced by press release.
- CommentaryPreliminary
Why lean-mass loss deserves more attention than it gets
Body-composition data from incretin trials is often reported as a footnote. For older adults it may be the most functionally important number in the study.
Community signal
What people are saying
Aggregate observation of public discussion, not user testimonials. Self-report is the weakest form of evidence — each dossier states why these reports can mislead.
- Melanotan II: Increased spontaneous arousal, described as beginning hours after administration (reported as helping)
- Melanotan II: Nausea, frequently severe enough that people pre-medicate or abandon use (also reported)
- Melanotan II: Pigmentation developing faster and deeper than with sun exposure alone (reported as helping)
- Melanotan II: New freckles and darkening of existing moles, reported commonly (also reported)
- Bremelanotide: Increased desire rather than purely physical response (reported as helping)
- Bremelanotide: Nausea, the dominant complaint and the usual reason for discontinuation (also reported)
- Semaglutide: Substantial appetite reduction, frequently described as the first time hunger felt manageable (reported as helping)
- Semaglutide: Nausea, constipation and reflux, the leading reasons for stopping (also reported)
- Tirzepatide: Greater appetite suppression than reported with semaglutide by people who used both (reported as helping)
- Tirzepatide: Gastrointestinal effects still the dominant complaint (also reported)
- Retatrutide: Faster loss than reported for approved incretins by people who used those first (reported as helping)
- Retatrutide: Gastrointestinal effects reported as more pronounced (also reported)
- Cagrilintide: Additional satiety on top of an incretin, reported by people already on one (reported as helping)
- Cagrilintide: Compounded gastrointestinal effects when combined (also reported)
- CJC-1295: Improved sleep depth, the most consistently reported effect by a clear margin (reported as helping)
- CJC-1295: Water retention and puffiness, especially early (also reported)
Regulatory watch
Status, stated precisely
- FDA·Under consideration
Pharmacy Compounding Advisory Committee discussion of several research peptides
Substances including BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax and Epitalon-related compounds were discussed. A committee discussion is a stage in an evaluation process. It is not a recommendation, a listing, or an approval.
- FDA·Not approved
Warning letter — benefit-oriented content alongside a research-use-only disclaimer
The letter treated benefit-oriented product descriptions, and the sale of bacteriostatic water beside injectable compounds, as evidence of intended human use. A research-use-only disclaimer did not neutralise that content.
- FDA·Not approved
Warning letter — research-use-only framing and human-directed marketing
An earlier letter in the same line of enforcement. Together these establish that site content, not the disclaimer, determines intended use.
- CDSCO·Restricted
New-drug pathway applies to first-time synthetic peptides
A peptide manufactured synthetically for the first time is treated as a new drug. The New Drugs and Clinical Trials Rules require Central Licensing Authority permission before import or manufacture for sale or distribution.
Quality Lab
A COA is only the beginning
A certificate of analysis tells you what one laboratory measured, on one batch, using methods it chose. Reading one is a skill — and knowing what it leaves out matters more than the number on the front page.
Identity vs purity
Two different questions. A pure sample of the wrong molecule still reads 99%.
HPLC chromatograms
What the peaks mean, and what a cropped chromatogram hides.
Mass spectrometry
Confirming what the molecule actually is.
Assay and peptide content
Why net peptide content differs from gross weight.
Counterions and residual solvents
The part of the mass that is not your peptide.
Sterility and endotoxin
Separate tests, separate failure modes.
Water content and stability
How degradation shows up over a product's life.
Accreditation and retention
Who tested it, to what standard, and whether it can be re-tested.
Questions
The things people ask us first
Straight answers, including the ones that are less convenient for us.
The developments that actually matter, with the evidence grade attached
Peptide science, longevity and metabolic health — summarised with evidence grades, sources and regulatory context. No protocols, no product pitches, no miracle claims.